ライフサイエンスコーパス: CYP19

1 etter discriminate with respect to CYP17 and CYP19.

2 ffects of these two SNPs on transcription of CYP19.

3 transcribed from the same strand, closer to CYP19.

4 the crucial steroidogenic enzymes, CYP17 and CYP19.

5 cardiovascular diseases, dual inhibition of CYP19 and CYP11B2 (aldosterone synthase) is a promising

6 on of important structural features of known CYP19 and CYP11B2 inhibitors, we succeeded in obtaining

7 p as potent and selective dual inhibitors of CYP19 and CYP11B2, especially compound 3p, which exhibit

8 exhibited IC(50) values of 32 and 41 nM for CYP19 and CYP11B2, respectively, and a high selectivity

9 ith IC(50) values around 50 and 20 nM toward CYP19 and CYP11B2, respectively.

10 It showed no inhibition of CYP17 and CYP19 and no mutagenic effects.

11 Dual inhibitors of aromatase (CYP19) and aldosterone synthase (CYP11B2) are therefore

12 selectivity over CYP11B1 (SF = 422), CYP17, CYP19, and a panel of hepatic CYP enzymes.

13 M) and excellent selectivities over CYP11B1, CYP19, and CYP3A4.

14 ncoding two steroidogenic enzymes, CYP17 and CYP19, and examining their expression patterns in the C.

15 was designed and synthesized as nonsteroidal CYP19 aromatase inhibitors.

16 a key steroidogenic enzyme [cytochrome P450(CYP19) aromatase] required for estrogen synthesis in ver

17 genetic polymorphisms in the aromatase gene, CYP19, as a step toward pharmacogenomic studies of aroma

18 Aromatase (CYP19) catalyzes the terminal step in estrogen biosynthe

19 Aromatase (CYP19) catalyzes three consecutive hydroxylation reactio

20 , MAPK6 or TLN2), placing it upstream of the CYP19 coding region in the opposite strand, whereas a de

21 sions were located 17-185 kb upstream of the CYP19 coding region.

22 e production of androgenic precursors, while CYP19 converts testosterone to estradiol.

23 All analyses excluded CYP19 cosegregation with PCOS, demonstrating that this l

24 We also analyzed KrasG12D;Cyp19-Cre and KrasG12;Pgr-Cre mutant mouse models that e

25 le arrest in granulosa cells of the KrasG12D;Cyp19-Cre mice but not in the KrasG12D;Pgr-Cre mice, doc

26 that did not occur in the Ptenfl/fl;KrasG12D;Cyp19-Cre or Ptenfl/fl;KrasG12D;Pgr-Cre mouse strains.

27 Here, the evolutionary origin of CYP19 duplication, and the evolution of the gene paralog

28 suiform relatives the peccaries experienced CYP19 duplication.

29 7 and rs7176005 in the 5'-flanking region of CYP19 exon 1.1) that were significantly associated with

30 trophoblast differentiation and induction of CYP19 expression are prevented.

31 form a multinuclear syncytiotrophoblast and CYP19 expression is markedly induced.

32 rget of Dax-1 in Leydig cells, and increased Cyp19 expression may account, in part, for the infertili

33 Elevated Cyp19 expression was accompanied by increased intratesti

34 n trophoblasts markedly inhibited endogenous CYP19 expression, differentiation of cultured human trop

35 mic sequences required for placenta-specific CYP19 expression, fusion genes containing 2,400 and 501

36 nt to elucidate the mechanisms that regulate CYP19 expression.

37 trophoblast differentiation and induction of CYP19 expression.

38 permia (NOA) revealed enhanced expression of CYP19, GAS6, and AXL, which suggests that the AROM+ mous

39 g DNA within 501 bp of exon I.1 of the human CYP19 gene contains cis-acting elements that bind placen

40 The CYP19 gene encodes for aromatase (P450arom), a key stero

41 hibitory effects of hypoxia and of Mash-2 on CYP19 gene expression in human placenta.

42 nt to elucidate the mechanisms that regulate CYP19 gene expression.

43 d within the 11.2 Mb region telomeric to the CYP19 gene in chromosome 15q21 cryptically upregulated a

44 ingle nucleotide polymorphisms (SNPs) in the CYP19 gene may alter the effectiveness of AI therapy in

45 In humans, aromatase P450 (product of CYP19 gene), which catalyzes conversion of C19 steroids

46 P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from an

47 P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from an

48 The enzyme is encoded by the CYP19 gene, which is expressed in a tissue-specific mann

49 estrogens by aromatase P450, product of the CYP19 gene.

50 were generated by targeted disruption of the cyp19 gene.

51 tochrome P450 (P450arom), the product of the cyp19 gene.

52 Expression of the aromatase (Cyp19) gene, which encodes the enzyme that converts test

53 Thus, suiform CYP19 genes arose from an ancestral duplication that has

54 intervening intron, representing duplicated CYP19 genes, were cloned and sequenced from collared pec

55 he hypothesis that women with the long-range CYP19 haplotype 2b-3c may be carriers of a predisposing

56 Expression of CYP19(I.1):hGH fusion genes containing as little as 501

57 ERalpha and aromatase (estrogen synthetase, CYP19) in midshipman.

58 uction and is encoded by a single copy gene (CYP19) in most mammals.

59 was found to be the best and most selective CYP19 inhibitor of them all.

60 decisive structural features of CYP11B2 and CYP19 inhibitors into a common template, a series of pyr

61 heses in peripheral tissue by the aromatase (CYP19) inhibitors applied.

62 e is known about whether common variation in CYP19 is associated with risk of hormone-related disease

63 Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and

64 Aromatase [cytochrome P450 19 (CYP19)] is a critical enzyme for estrogen biosynthesis,

65 B1 and good selectivity over human CYP17 and CYP19, it is a promising candidate for further developme

66 An increase in allele sharing at the CYP19 locus has been demonstrated in 2 large samples of

67 proximately 2.6 kb) spanning 189.4 kb of the CYP19 locus to characterize linkage disequilibrium (LD)

68 a polymorphic tetranucleotide marker at the CYP19 locus using fluorescence-based semiautomated genot

69 An increase in allele sharing at the CYP19 locus was observed in the first data set of 225 AS

70 genes on chromosomes 2 (NIDDM1) and 15 (near CYP19) makes a contribution to susceptibility to type 2

71 These data provide preliminary evidence that CYP19 may have a role in RA susceptibility.

72 ervations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiolo

73 m of the translation initiation site created CYP19 mRNA encoding functional aromatase protein.

74 lizards compared to receptive PreOv animals; CYP19 mRNA levels in the VMN did not change across the o

75 The 5' untranslated regions of CYP19 mRNA transcripts in these tissues are encoded by d

76 In placenta, the 5' untranslated region of CYP19 mRNA transcripts is encoded by exon I.1, which lie

77 s that direct inappropriate transcription of CYP19 or other critical genes.

78 Previously, we found that Mash-2 inhibited CYP19 promoter activity through sequences within a 350-b

79 ion of cultured human trophoblast cells, and CYP19 promoter activity.

80 sed the SF-1-mediated transactivation of the Cyp19 promoter but did not inhibit the StAR or Cyp11a pr

81 A single gene (CYP19), regulated via tissue-specific promoters, encodes

82 No differences in CYP19 sequence were observed between tumor and germ-line

83 AMP-->PKA-->CREB pathway leading to enhanced CYP19 transcription and increased aromatase activity.

84 E(2) (PGE(2)) that mediate the induction of CYP19 transcription in human adipocytes and breast cance

85 d a portion of the 3'-untranslated region of CYP19 using 240 DNA samples from four ethnic groups.

86 genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aro

87 more, selectivities over CYP11B2, CYP17, and CYP19 were observed, as well as satisfying metabolic sta

88 Apart from rare mutations in CYP19 which result in severe phenotypes associated with

89 sgenic mouse strain that overexpresses human CYP19, which encodes aromatase (AROM+ mice), and mice wi

90 side chain cleavage (CYP11a) and aromatase (CYP19), with PCOS in 20 multiply-affected families.